Navigation Links
AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
Date:5/19/2009

    Partner Keryx to present Phase 2 data on perifosine for multiple cancers

QUEBEC CITY, May 19 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AEZS-108, in prostate cancer, will be presented as a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 through June 2, 2009 at the Orange County Convention Center in Orlando, Florida.

AEZS-108

Results presented are important for the expansion of potential indications for AEZS-108. While clinical investigations so far focused on gynaecological indications, the new results show continued expression of Luteinizing Hormone Releasing Hormone (LHRH) receptors in prostate cancer specimens after prolonged use of LHRH agonists; these data provide further support to the investigation of the drug in hormone-refractory prostate cancer, a major genitourinary cancer indication in male patients.

Abstract selected for presentation is as follows:

Genitourinary Cancer

Sunday, May 31, 2009:

# 5103: Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists

Lead Author: Stephen Liu, MD

Poster Session: 2 pm - 6 pm (Level 2, West Hall C)

Perifosine

Additionally, AEterna Zentaris' partner, Keryx Biopharmaceuticals, announced yesterday that it will present four posters on the Akt-inhibitor compound, perifosine, during the ASCO meeting. Keryx is currently developing perifosine in multiple Phase 2 trials for various types of cancer. All of the clinical data presented demonstrate the potential efficacy of perifosine, both as a single agent and in combination with other approved agents, in the treatment of patients with advanced renal cell carcinoma, colorectal cancer and GIST (gastrointestinal stromal tumors).

Abstracts selected for presentation are as follows:

Renal Cell Carcinoma (RCC)

Friday, May 29, 2009

#5034: Phase 2 study of perifosine in metastatic renal cell carcinoma (RCC) progressing after prior therapy (Rx) with a VEGF receptor inhibitor.

Lead Author: Nicholas Vogelzang, MD

Poster Discussion: 5 pm - 6 pm (Level 2, West Hall F5)

Sunday, May 31, 2009

#5101: A Phase 2 trial of perifosine in patients with advanced renal cell carcinoma (RCC), who have failed tyrosine kinase inhibitors (TKI).

Lead Author: Daniel Cho, MD

Poster Session: 2 pm - 6 pm (Level 2, West Hall C)

Colorectal Cancer

Sunday, May 31, 2009

#4081: Randomized Phase 2 study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer.

Lead Author: Sasha Vukelja, MD

Poster Session: 8 am - 12 pm (Level 2, West Hall C)

Gastrointestinal Stromal Tumor (GIST)

Sunday, May 31, 2009:

#10563: A randomized Phase 2 study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST).

Lead Author: Anthony Conley, MD

Poster Session: 2 pm - 6 pm (Level 2, West Hall C)

Copies of all of these abstracts are currently available and can be viewed on-line through the ASCO website: http://www.asco.org/.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the AEterna Zentaris' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements and disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
2. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
3. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
4. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
5. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
6. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
7. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
8. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
9. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
10. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
11. AEterna Zentaris Reports Third Quarter 2008 Financial and Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, ... Scientific Advisory Board. Dr. Lamka will assist PathSensors in expanding the use of ... PathSensors deploys the CANARY® test platform for the detection of harmful pathogens, including ...
(Date:4/27/2016)... , ... April 27, 2016 , ... Global Stem ... GSCG Advisory Board. Ross is the founder of GSCG affiliate Kimera Labs in Miami. ... where he studied hematopoietic stem cell transplantation for hematologic disorders and the suppression of ...
(Date:4/27/2016)... MedDay, a biotechnology company focused on the treatment of ... as Chairman of its Board of Directors. Catherine ... who contributed to the rapid development of the Company since ... her career in strategy consulting and investment banking in ...  She held C-Suite level roles in some of ...
(Date:4/26/2016)... LOS ANGELES, Calif. (PRWEB) , ... April 27, ... ... Los Angeles office of Lewis Roca Rothgerber Christie LLP as an associate in ... and prosecuting U.S. and international electrical, mechanical and electromechanical patent applications. He has ...
Breaking Biology Technology:
(Date:3/14/2016)... 2016 NXTD ) ("NXT-ID" or the ... announces the airing of a new series of commercials on ... March 21 st .  The commercials will air on Bloomberg ... on the Street show. --> NXTD ) ("NXT-ID" ... commerce market, announces the airing of a new series of ...
(Date:3/11/2016)... 11, 2016 --> ... report "Image Recognition Market by Technology (Pattern Recognition), by ... by Deployment Type (On-Premises and Cloud), by Industry Vertical ... by MarketsandMarkets, the global market is expected to grow ... Billion by 2020, at a CAGR of 19.1%. ...
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
Breaking Biology News(10 mins):